Contrast Media For Medical Imaging
Voyageur is building a fully integrated supply chain, delivering high quality products to the market.
Our Mission
To become a vertically integrated global leader in medical imaging contrast media by developing cost-effective and best in class products. We are experts in mineral mining and processing. Our ownership of natural barium and iodine resources within North America enables us to implement a strategy aimed at building a stable supply chain for imaging products critical for patient diagnosis. We have assembled a team of contrast media experts and world leading radiologists to drive our decision making for this important patient-led initiative, the starting point being several Health Canada licenses already approved for barium contrast media. Voyageur is now working with the FDA to register our products in the US market, whilst creating a drug dossier for the European and International markets. Our long term vision is to serve both the barium and iodine contrast media markets, from a fully integrated supply chain: “From The Earth To The Bottle”.
Our Products
INTRODUCTION
Why Are We Here?
Barium sulfate and Iodine- based contrast agents are used for many CT, MR and fluoroscopic imaging procedures
Voyageur wholly owns high purity pharmaceutical-grade barium and early-stage iodine brine project. Positioning Voyageur to address the concerns of the current shortages and increasing cost of these APIs for medical imaging
Voyageur is uniquely positioned to be highly competitive in this multi-billion-dollar market
30 years
Message from CEO, Mr. Brent Willis, Voyageur Pharmaceuticals Ltd. (“Voyageur”)
Dear Voyageur Investor,
Voyageur founders are experts in mineral mining and processing, they have assembled a team of contrast media experts and world leading doctors from the radiology pharmaceutical industry. We have received Health Canada licenses for barium contrast media and have begun to create and market products for Canada. Voyageur owns barium and iodine resource, and can implement a strategy to eliminate all middlemen in the supply chain to reduces overall costs. Once this strategy is accomplished, the company will receive the highest profit margin possible for our active pharmaceutical ingredients (API).
Voyageur is working with the FDA to register our products in the US markets and we are creating a drug dossier for the European and International markets. Voyageur has a long term vision of fully integrating both the barium and iodine contrast media markets, to allow our company to compete and to achieve a high growth rate and strong return on investment for our shareholders.